Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to -$62.1 million.

  • Relay Therapeutics' Cash from Operations rose 1726.62% to -$62.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$248.5 million, marking a year-over-year increase of 1140.01%. This contributed to the annual value of -$249.1 million for FY2024, which is 1705.17% up from last year.
  • As of Q3 2025, Relay Therapeutics' Cash from Operations stood at -$62.1 million, which was up 1726.62% from -$55.3 million recorded in Q2 2025.
  • Over the past 5 years, Relay Therapeutics' Cash from Operations peaked at $46.6 million during Q1 2021, and registered a low of -$89.2 million during Q4 2023.
  • In the last 5 years, Relay Therapeutics' Cash from Operations had a median value of -$57.9 million in 2024 and averaged -$54.9 million.
  • As far as peak fluctuations go, Relay Therapeutics' Cash from Operations soared by 30882.96% in 2021, and later crashed by 20543.1% in 2022.
  • Relay Therapeutics' Cash from Operations (Quarter) stood at -$39.7 million in 2021, then tumbled by 43.75% to -$57.1 million in 2022, then crashed by 56.25% to -$89.2 million in 2023, then skyrocketed by 35.12% to -$57.9 million in 2024, then decreased by 7.35% to -$62.1 million in 2025.
  • Its Cash from Operations was -$62.1 million in Q3 2025, compared to -$55.3 million in Q2 2025 and -$73.2 million in Q1 2025.